International Journal of Clinical and Experimental Medicine Research

ISSN Print: 2575-7989 Downloads: 152798 Total View: 2063422
Frequency: quarterly ISSN Online: 2575-7970 CODEN: IJCEMH
Email: ijcemr@hillpublisher.com

Location: Home >> Special Issue

Special Issue

Antibody drugs: especially monoclonal and bispecific antibodies

Dear colleagues,

The special issue on "Antibody Drugs: Especially Monoclonal and Bispecific Antibodies" highlights the significant advancements and innovations in the field of antibody therapeutics. Monoclonal Antibodies (mAbs) are engineered antibodies designed to target specific antigens on cancer cells or other disease targets. Bispecific Antibodies (BsAbs) focuses on the unique properties of bispecific antibodies, which can bind to two different targets simultaneously. The versatility of BsAbs allows for innovative therapeutic approaches, especially in redirecting immune responses against tumors, thereby providing insights into their potential advantages and ongoing clinical developments. This special issue aims to contribute to the understanding of antibody drugs and foster further research and innovation in this critical area of therapeutic development. It including but not limited to the following topics:

Monoclonal Antibodies (mAbs)
Bispecific Antibodies (BsAbs)
Targeted Therapy
Immune Modulation
Antigen-Antibody Interaction
Therapeutic Applications
Cancer Immunotherapy
Fc Region Engineering
Hybridoma Technology
Epitope Targeting
Mechanisms of Action
Clinical Trials
Biologics
Pharmacokinetics
Drug Development

Guest Editors

Manuscript Submission Information

Authors should submit their manuscripts for the special issue by emailing them as an attachment to specialissue@hillpublish.com or by using the online submission system. The manuscript should be submitted by one of the authors, and submissions by anyone other than the authors will not be accepted. Additionally, the submitted manuscript should include a cover letter that specifies the special issue to which the manuscript is being submitted.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). The submitted papers should be properly formatted and written in fluent English. All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Guidelines page.

Deadline for manuscript submissions

December 31, 2024

List of Publications in This Special Issue